Nexvet expands veterinary biologics research team
15 September, 2014 by Dylan Bushell-EmblingTwo former CSL (ASX:CSL) scientists have joined Nexvet's veterinary biologics research centre in Melbourne.
Calzada, pSivida, GI Dynamics announce board moves
12 September, 2014 by Dylan Bushell-EmblingCalzada (ASX:CZD) has announced the resignation of an independent director, while GI Dynamics (ASX:GID) and pSivida (ASX:PVA) have selected new members for their own boards.
Global Kinetics gets FDA clearance for PKG
11 September, 2014 by Dylan Bushell-EmblingGlobal Kinetics has been cleared to sell the Australian-made Parkinson's KinetiGraph wearable symptom monitoring device in the US.
AusBiotech calls for nominations to the board of directors
11 September, 2014Further to the notice of the forthcoming election for AusBiotech's board of directors, nominations are now open for eligible AusBiotech members.
Iluvien approved in 10th EU market: pSivida
11 September, 2014 by Dylan Bushell-EmblingpSivida (ASX:PVA) licensee Alimera Sciences has got the marketing nod in Sweden for DMO treatment Iluvien, marking its 10th EU approval.
Bronchitol effective in high-risk bronchiectasis patients
10 September, 2014 by Dylan Bushell-EmblingPharmaxis' (ASX:PXS) Bronchitol may have missed its main endpoint in last year's bronchiectasis trial, but new analysis shows a statistically significant improvement in high-risk patients.
Invion ready to escalate dose in lupus trial
10 September, 2014 by Dylan Bushell-EmblingAnalysis of safety data from the first two cohorts involved in Invion's (ASX:IVX) trial of INV103 in lupus has given the company the confidence to step up the dose for the next stage.
Patents enabling and supporting medical research and resulting tests, vaccines and treatments
09 September, 2014Patents are at the core of enabling genetic tests, treatments, vaccines and cures resulting from medical research, says AusBiotech - contrary to reports stemming from last week's Federal Court decision in the D'Arcy v Myriad Genetics case that claim research is being stifled.
Viralytics CEO, biotech veteran join company board
09 September, 2014 by Dylan Bushell-EmblingFormer CSL (ASX:CSL) executive Peter Turvey has been named a Viralytics (ASX:VLA) non-executive director, while Viralytics CEO Malcolm McColl will take the role of managing director.
ResMed settles dispute with APEX Medical
06 September, 2014 by Dylan Bushell-EmblingResMed (ASX:RMD) has declared a truce in its copyright infringement war with Taiwan's APEX Medical, signing a confidential settlement.
Antisense's ATL1103 shows promise in acromegaly
05 September, 2014 by Dylan Bushell-EmblingAntisense Therapeutics' (ASX:ANP) ATL1103 candidate reduced sIGF-I levels in patients with the growth disorder acromegaly during a phase II trial.
Action urged to capitalise on opportunity as Budget tables reveal loss of support
04 September, 2014The release of the federal government's Science, Research and Innovation Budget Tables this week reveals the losses of almost $400m to science, research and innovation, prompting AusBiotech to reinforce its calls for urgent and specific action that will drive growth in the biotechnology industry and, therefore, the Australian economy.
GSK to shut down Medicines Research Unit
04 September, 2014 by Dylan Bushell-EmblingGSK will cease operation of its research unit at Sydney's Prince of Wales Hospital at the end of the month, laying off eight employees and five contractors.
Pharmaxis to take anti-inflammatory to human trials
03 September, 2014 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) plans to conduct the first human trials of PXS4728A - a drug candidate for inflammatory diseases including COPD and NASH - in 1Q15.
PAP therapy saves lives in heart patients: ResMed
02 September, 2014 by Dylan Bushell-EmblingPositive airway pressure (PAP) therapy in heart patients with sleep apnoea can reduce mortality rates by up to 38%, analysis from ResMed (ASX:RMD) suggests.
